Latest Safety News

Saferoads Holdings (ASX: SRH) has acquired Chameleon AMLS, adding a new modular trailer product line and appointing its founder Andrew Kaye to the board.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

Alterity Therapeutics has clinched FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy, with the trial set to begin by the end of 2026.

Maritana Minerals has increased the processing capacity of its Black Swan Processing Hub to 2.5 million tonnes per annum, with construction set to begin mid-2026 and first production expected in the second half of 2027.

Emperor Energy has submitted a revised Environmental Plan for its Judith-2 appraisal well and is advancing drilling preparations, including securing contractors and negotiating the Valaris-107 rig contract for a late Q1 2027 start.

dorsaVi reveals that integrating RRAM and neuromorphic computing into its sensor platform could halve sensor count and more than double battery life in lower-limb exoskeletons, positioning the company as a key intelligence partner in a $1.79 billion market.

Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.

Nyapiri Macro Mining, a majority Indigenous-owned contractor, has landed its inaugural $12.52 million work package under a BHP framework agreement, marking its emergence as a Tier-1 Pilbara mining services provider.

EQ Resources has secured board approval for a A$39 million expansion at its Mt Carbine tungsten mine, aiming to double crushing capacity and boost annual production by 500 tonnes amid strong tungsten prices.

Cynata Therapeutics secures a crucial regulatory green light from the EMA’s Paediatric Committee for its CYP-001 treatment in children with acute graft versus host disease, paving the way for sequential adult and paediatric trials in Europe.

Opthea Limited resumes ASX trading as it pivots to develop OPT-302 for lymphangioleiomyomatosis, outlining a disciplined 18-month staged clinical program backed by A$31.2 million in cash.

Qoria Limited has dispatched its Scheme Booklet to shareholders detailing the proposed acquisition by Aura Consolidated Group. While the independent expert finds the deal not fair but reasonable, Qoria’s board unanimously recommends approval, pending no superior proposal.